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gene ofﬁ cial symbol gene name location
clinical 
presentation
Possible pathways /
 pathological biological processes
mendeliAn genes
MAPT Microtubule-associated protein tau 17q21.1 FTD Toxic aggregation (defect in neuronal cytoskeleton)
GRN Granulin 17q21.32 FTD* Autophagy; lysosomal pathway; infl ammation
TREM2 Triggering receptor expressed on myeloid cells 2 6p21.1 FTD Infl ammation
CHMP2B Charged multivesicular body protein 2B 3p11.2 FTD Autophagy; lysosomal pathway
C9orf72 Chromosome 9 open reading frame 72 9p21.2 FTD, ALS Toxic RNA or repeat dipeptides aggregation
SQSTM1 Sequestosome 1 5q35 FTD, ALS* Autophagy
UBQLN2 Ubiquilin 2 Xp11.21 FTD, ALS* Autophagy
VCP Valosin-containing protein 9p13.3 FTD, ALS* Autophagy
OPTN Optineurin 10p13 FTD/ALS* Autophagy
SOD1 Superoxide dismutase 1, soluble 21q22.11 ALS Toxic aggregation; free radical scavenger enzyme
FUS FUS RNA binding protein 16p11.2 ALS DNA/RNA metabolism
TARDBP TAR DNA binding protein 1p36.22 ALS DNA/RNA metabolism
CHCHD10 Coiled-coil-helix-coiled-coil-helix domain containing 10 22q11.23 FTD, ALS Mitochondrial function
ALS2 Amyotrophic lateral sclerosis 2 (juvenile) 2q33.1 ALS* Modulator for endosomal dynamics
SPG11 Spastic paraplegia 11 (autosomal recessive) 15q14 ALS* DNA damage repair
SETX Senataxin 9q34.13 ALS* DNA/RNA processing
MATR3 Matrin 3 5q31.2 ALS* DNA/RNA metabolism
ANG Angiogenin, ribonuclease, RNase A family, 5 14q11.1-q11.2 ALS Blood vessel formation
VAPB VAMP (vesicle-associated membrane protein)-associated 
protein B and C
20q13.33 ALS* Vesicle traffi cking
PFN1 Profi lin 1 17p13.3 ALS Actin dynamics 
TAF15 TAF15 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 68kDa
17q11.1-q11.2 ALS RNA metabolism
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 12q13.1 ALS, FTD* RNA metabolism; direct interaction with TDP-43
HNRNPA2B1 Heterogeneous nuclear ribonucleoprotein A2/B1 7p15 ALS, FTD* RNA metabolism; direct interaction with TDP-43
ERBB4 Erb-b2 receptor tyrosine kinase 4 2q33.3-q34 ALS Dysregulation of the neuregulin-ErbB4 pathway
ARHGEF28 Rho guanine nucleotide exchange factor (GEF) 28 5q13.2 ALS Interaction with low-molecular-weight neurofi lament mRNA
DAO D-amino-acid oxidase 12q24 ALS
GLE1 GLE1 RNA export mediator 9q34.11 ALS RNA metabolism
SIGMAR1 Sigma non-opioid intracellular receptor 1 9p13.3 ALS, FTD Endoplasmic reticulum lipid rafts
ERLIN2 ER lipid raft associated 2 8p11.2 ALS* Endoplasmic reticulum lipid rafts
PNPLA6 Patatin-like phospholipase domain containing 6 19p13.2 ALS* Neurite outgrowth and process elongation 
PRKAR1B Protein kinase, cAMP-dependent, regulatory, type I, beta 7p22 FTD* Regulation of metabolism, ion transport, and gene transcription
DCTN1 Dynactin 1 2p13 ALS* Vesicle traffi cking
risk or modifier genes
TMEM106B Transmembrane protein 7p21.3 FTD Regulation of lysosomal function and progranulin pathways
ATXN2 Ataxin 2 (susceptibility) 12q24.1 FTD/ALS Modifi er of tdp-43 toxicity
UNC13A/ KCNN1 Unc-13 homolog A (C. elegans)/potassium channel, 
calcium-activated intermediate/small conductance subfamily 
N alpha, member 1
19p13.11 
/19p13.1
ALS Neurotransmitter release/neuronal excitability 
ZNF512B Zinc fi nger protein 512B 20q13.33 ALS
FTD ALS
SOD1
F
R
E
Q
U
E
N
C
Y
 I
N
 F
A
M
IL
IA
L
 C
A
S
E
S
FUS
TARDBP
C9orf72
GRN
CHMP2B
MAPT
5%
10%
15%
20%
25%
30%
TREM2
VCP
SQSTM1
OPTNUBQLN2
CHCHD10
Main genes associated with the clinical FTD-ALS spectrum Phenotype overlaps and pleiotropy 
associated with genetic ALS
ALS SETX
Spastic
paraplegia
AOA2
Cerebellar
ataxia
ParkinsonismPsychosis
POAG SMA/PMA
OPTN
FIG4
C9orf72 DCTN1 SOD1
VAPB
ANG
SPG11
ATXN2
CMT
neuropathy
CHCHD10
ALS2
Dystonia
SPAST
ERLIN2
PNPLA6
SnapShot: Genetics of ALS and FTD
Rita Guerreiro, José Brás, and John Hardy 
Department of Molecular Neuroscience, Institute of Neurology, University College London,  
Queen Square, London WC1N 1PJ, UK
Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are considered to be part of a spectrum. Clinically, FTD patients present with dementia frequently charac-
terized by behavioral and speech problems. ALS patients exhibit alterations of voluntary movements caused by degeneration of motor neurons. Both syndromes can be present 
within the same family or even in the same person. The genetic findings for both diseases also support the existence of a continuum, with mutations in the same genes being 
found in patients with FTD, ALS, or FTD/ALS.
The figure on the left represents the distribution of genes according to their associated phenotype and mutation frequency in familial cases (this can vary between cohorts 
or populations).
Some cases of mutations in genes represented in the extremes of the graph (associated with either ALS or FTD) have also been described as associated with the other clinical 
phenotypes. For example, mutations in TARDBP that are the cause of ALS have, in rare occasions, been described in cases presenting with FTD. The genetic evidence for these 
associations is weak (mainly lacking segregation of the variants with the phenotypes or strong evidence of pathogenicity), and for these reasons, such genes are represented 
as the extremes of the FTD-ALS continuum.
Genetic ALS is usually not only associated with motor systems degeneration but also, very frequently, occurs in combination with degenerative processes like parkinsonism 
or ataxia. In fact, very few ALS genes have been associated with a strict motor-only phenotype, and genes commonly associated with other diseases have sometimes been 
found to be the cause of ALS. This was the case for FIG4 and SPAST mutations that have been originally associated with Charcot-Marie-Tooth neuropathy type 4J (CMT4J) and 
autosomal-dominant spastic paraplegia-4 (SPG4), respectively, and have been subsequently found to be mutated in ALS cases.
These overlaps between different phenotypes and genes found to be mutated either in ALS with additional features or in other diseases and ALS are represented in the right panel.
One FTD gene (PRKAR1B) and several ALS genes (ARHGEF28, for example) have been, so far, only reported in a single family (with different levels of segregation) or have not yet 
been independently replicated. PRKAR1B was identified in an FTD-like family with a syndrome considered to be novel. The family presented dementia and/or parkinsonism in 12 
affected individuals and a unique neuropathology displaying abundant neuronal inclusions by hematoxylin and eosin staining throughout the brain with immunoreactivity for inter-
mediate filaments. Some ALS genes have conflicting results with variants described in controls and uncertain pathogenicity attributed to different mutations (ANG, for example).
Several genes implicated in FTD and ALS have possible functions within the same biological pathways such as autophagy and the lysosomal pathway, maintenance of neu-
ronal cytoskeleton, and DNA/RNA metabolism. In some cases, genes also share similar domains like the RNA binding genes with prion-like domains HNRNPA1, HNRNPA2B1, 
TARDBP, FUS, TAF15, and EWSR1. In fact, TAF15 and EWSR1 were screened for the identification of variants because of their commonalities with FUS and TARDBP. In both 
genes, variants were found in patients with sporadic ALS, and weak familial segregation has only been demonstrated for TAF15.
The use of next-generation sequencing technologies has recently allowed the identification of rare variants in TUBA4A to be associated with ALS, and the analyses of de novo 
mutations in sporadic ALS trios have identified mutations in SS18L1. Again, the approaches used did not allow for segregation analyses and, for this reason, even though the 
variants were associated with familial ALS, the genes are not included as a Mendelian gene for ALS in the table.
Other genes have been reported as susceptibility or modifiers of FTD and/or ALS with different levels of evidence. These include, in addition to the ones represented in the 
table, BTNL2/HLA-DRA/HLA-DRB5, RAB38/CTSC, CHRNA3/4, CHRNB4, PRPH, CHGB, NEFH, VEGF, HFE, PON1/2/3, DPP6, ELP3, ITPR2, FGGY, CHGB, DPYSL3, KIFAP3, 
EPHA3/4, PPARGC1A, APOE, MAOB, CX3CR1, and SMN1.
The loci identified by genome-wide association studies are named according to the closest gene to the most significant hit at each locus. It is possible that the gene involved 
in FTD and/or ALS is not the closest but is in linkage disequilibrium with the true hit. This has been recently shown to be the case for UNC13A, where KCNN1 (a nearby gene) 
was implicated by eQTL analysis.
An asterisk (*) indicates genes for which mutations may present additional phenotypes or be the cause of different clinical syndromes. For example, loss-of-function hetero-
zygous mutations in GRN cause FTD, whereas homozygous mutations in the same gene have recently been reported to cause neuronal ceroid lipofuscinosis-11 (CLN11); VCP 
mutations are known to cause ALS with or without FTD and inclusion body myopathy with Paget disease of bone and frontotemporal dementia (IBMPFD).
AbbreviAtions
CMT neuropathy, Charcot-Marie-Tooth neuropathy; POAG, primary open angle glaucoma; SMA/PMA, spinal muscular atrophy/progressive muscular atrophy; AOA2, Ataxia with 
oculomotor apraxia type 2.
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